
The introduction of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of metastatic renal cell carcinoma (mRCC) [1]. The expression of programmed death‐ligand 1 (PD‐L1) as assessed by immunohistochemistry (IHC) has been extensively studied as predictive biomarker for patients receiving ICIs. However, results in clinical RCC trials concerning the predictive value of PD‐L1 expression
Like
Save
Share